Haisco Pharmaceutical Group Co. Ltd. Class A 002653

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

Phase 2b dose ranging data presented at ERS show both doses of AN01 delivered significant and clinically relevant improvements in lung function versus placebo at Week 4Trial comprised of broad COPD population, including participants on background single or dual bronchodilator therapy AN01 was well tolerated with no treatment-related adverse events reported in the 0.75 mg dose group, the dose under investigation in the Phase 3 program AirNexis has completed its Phase 1 multiple ascending dose (MA

On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners ("ARCH"), to grant Sentivera the rights to develop, manufacture, and commercialize its independently developed one pre-clinical innovative drug globally, excluding Greater China.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization.The Company’s lead drug candidate, Ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH Previously Untreated with Complement Inhibitors.Completed follow-on offeri

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights:Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal,

Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.

On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding Greater China, as well as its independently developed innovative drug HSK39297 worldwide, excluding Greater

Nuvectis Pharma Inc (NASDAQ:NVCT) shares gained 5. 7% in premarket trading on Monday after the company announced a licensing agreement with Haisco Pharmaceutical Group that grants it exclusive rights outside China to two late-stage clinical assets.

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies.NXP100 (HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated dise

Eli Lilly (NYSE:LLY) has agreed to acquire three vaccine and infectious disease companies, Curevo, LimmaTech Biologics, and Vaccine Company, in deals totaling nearly US$4b. The acquisitions expand Eli Lilly's reach beyond its core obesity and diabetes franchises into vaccines and infectious diseases. Alongside these acquisitions, Eli Lilly has recently entered partnerships in genetic and RNA based therapies with groups including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical...

Eli Lilly (NYSE:LLY) is pushing beyond its obesity drug franchise with plans to acquire three vaccine focused biotech companies. The company has also entered new collaborations in genetic and RNA based therapies with partners including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical Group. These moves come alongside broader offerings on LillyDirect, signaling a wider repositioning of its product pipeline. Eli Lilly, trading at $1,131.42, has seen very large share price gains...

Eli Lilly and Co. announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs. The deals come as investors also evaluate positive Phase 3...

On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas.

AbbVie Inc. (NYSE:ABBV) is one of the top S&P 500 stocks by index weight. On April 13, AbbVie Inc. (NYSE:ABBV) entered into an exclusive licensing agreement with Haisco Pharmaceutical Group for the development of pain medicines. Under the terms of the agreement, AbbVie will own the rights to develop, manufacture, and commercialize novel pain treatment […]

On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop, manufacture, and commercialize its independently developed innovative drug HSK39004 globally, excluding Greater China. The total deal value reaches up to USD 1.063 billion, including an upfront payment of USD 108 million (USD 40 million in cash and USD